Zanvia-M 50/500 Tablet is a combination oral antidiabetic medication containing Sitagliptin 50 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances the incretin system, resulting in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake. The combination of these two agents provides complementary mechanisms to improve glycemic control in patients inadequately controlled by diet, exercise, or monotherapy. Zanvia-M 50/500 is typically administered orally, with dosage individualized based on glycemic response and tolerability. It is important to monitor renal function prior to and during therapy due to the risk of metformin-associated lactic acidosis, especially in patients with renal impairment. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. Patients should be advised to maintain adequate hydration and report any symptoms suggestive of lactic acidosis immediately. Zanvia-M 50/500 should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular monitoring of blood glucose levels.